Proteasome inhibitors (PIs) are a fascinating class of small molecules that disrupt protein
homeostasis and are highly efficacious in the blood cancer multiple myeloma. However, PIs …

It is becoming clear that myeloma cell-induced disruption of the highly organized bone
marrow components (both cellular and extracellular) results in destruction of the marrow and …

ABSTRACT Introduction: Proteasome inhibitors (PIs) are therapeutic backbones of multiple
myeloma treatment, with PI-based therapies being standards of care throughout the …

Simple Summary In the last decade, proteasome inhibitors (PIs) have become a standard for
the treatment of multiple myeloma (MM). As a consequence of the pleiotropic effects of PIs …

Proteasome inhibitors have shown relevant clinical activity in several hematological
malignancies, namely in multiple myeloma and mantle cell lymphoma, improving patient …

Multiple myeloma (MM) is a plasma cell disorder typically characterized by abundant
synthesis of clonal immunoglobulin or free light chains. Although incurable, a deeper …

The connections between metabolic state and therapy resistance in multiple myeloma (MM)
are poorly understood. We previously reported that electron transport chain (ETC) …

Background Resistance to proteasome inhibitors (PIs) is a major obstacle to the successful
treatment of multiple myeloma (MM). Many mechanisms have been proposed for PI …

Proteasome inhibitors (PIs) have been a kind of backbone therapies for newly diagnosed as
well as relapsed or refractory myeloma patients in the last two decades. Bortezomib, the first …

The development of proteasome inhibitors (PIs) has transformed the treatment of multiple
myeloma and mantle cell lymphoma. To date, two PIs have been FDA approved, the …